<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03426111</url>
  </required_header>
  <id_info>
    <org_study_id>PI17-00499</org_study_id>
    <nct_id>NCT03426111</nct_id>
  </id_info>
  <brief_title>Multicenter, Randomized, Controlled and Double-blind Study of Efficacy and Safety of Endoscopic Gastric Tubulization in Patients With Non-alcoholic Steatohepatitis (NASH-APOLLO).</brief_title>
  <acronym>NASH-APOLLO</acronym>
  <official_title>Multicenter, Randomized, Controlled and Double-blind Study of Efficacy and Safety of Endoscopic Gastric Tubulization in Patients With Non-alcoholic Steatohepatitis (NASH-APOLLO).</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Puerta de Hierro University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hospital Universitario Ramon y Cajal</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospital Universitario Marqués de Valdecilla</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospitales Universitarios Virgen del Rocío</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Puerta de Hierro University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Nonalcoholic steatohepatitis is a growing public health problem affecting over 5% of the
      population. These patients are at increased risk of cardiovascular and liver-related death
      and have higher rates of malignancy.

      The currently standard of care is weight loss and physical exercise, with histological and
      analytical improvement in patients achieving a 5-10% reduction in body weight. However, less
      than 25% of the subjects achieve this goal. In obese patients , restrictive surgical
      treatments and gastric bypass have been successful in improving the metabolic syndrome,
      insulin resistance and liver histology.

      Currently, less invasive and less costly endoscopic techniques are being developed. These
      techniques also achieve a gastric restriction with similar results than bariatric surgery.
      One of these is the OverStitch® system (Apollo Endosurgery, Austin, TX, USA). Our aim is to
      evaluate the efficacy and safety of this method in the improvement of liver histology in
      obese patients with nonalcoholic steatohepatitis.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">February 2018</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Multicenter, randomized,controlled and double-blind study with two parallel arms, placebo (normal endoscopy and lifestyle modification) or endoscopic gastric tubulization with OverStitch® system (Apollo Endosurgery, Austin, TX, USA) and lifestyle modification.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To evaluate the efficacy of gastric tubulization + modification in lifestyle for 72 weeks compared to standard treatment / placebo in the resolution of NASH without worsening of fibrosis.</measure>
    <time_frame>72 weeks</time_frame>
    <description>NASH resolution is defined as the disappearance of ballooning and the disappearance or persistence of minimal lobular inflammation (grade 0 or 1) The worsening of fibrosis is defined as the progression of at least one stage.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of patients with improvement of fibrosis according to the CRN score NASH.</measure>
    <time_frame>72 weeks</time_frame>
    <description>to evaluate other histological changes after 72 weeks of treatment (CRN)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Non alcoholic fatty liver disease (NASH) activity score (NAS).</measure>
    <time_frame>72 weeks</time_frame>
    <description>Number of patients with improvement in histological scores CRN score on NASH (NAS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>steatosis-activity-fibrosis index score (steatosis activity fibrosis, SAF).</measure>
    <time_frame>72 weeks</time_frame>
    <description>Number of patients with improvement in the SAF score.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiovascular and death events related to the liver</measure>
    <time_frame>72 weeks</time_frame>
    <description>To evaluate the CV events in patients treated with gastric endoscopic tubulization + lifestyle modification with respect to lifestyle modification / placebo</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in liver enzymes</measure>
    <time_frame>72 weeks</time_frame>
    <description>To evaluate liver enzymes in patients treated with gastric endoscopic tubulization + lifestyle modification with respect to lifestyle modification / placebo</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in the noninvasive markers of fibrosis and steatosis</measure>
    <time_frame>72 weeks</time_frame>
    <description>To evaluate the noninvasive markers in patients treated with gastric endoscopic tubulization + lifestyle modification with respect to lifestyle modification / placebo</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in lipid parameters</measure>
    <time_frame>72 weeks</time_frame>
    <description>To evaluate the lipid parameters in patients treated with gastric endoscopic tubulization + lifestyle modification with respect to lifestyle modification / placebo</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Variation in body weight</measure>
    <time_frame>72 weeks</time_frame>
    <description>To evaluate body weight in patients treated with gastric endoscopic tubulization + lifestyle modification with respect to lifestyle modification / placebo</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biomarkers of endothelial and macrophage dysfunction</measure>
    <time_frame>72 weeks</time_frame>
    <description>To evaluate macrophage function in patients treated with gastric endoscopic tubulization + lifestyle modification with respect to lifestyle modification / placebo</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in markers of homeostasis of glucose and insulin resistance</measure>
    <time_frame>72 weeks</time_frame>
    <description>To evaluate the glucose metabolism in patients treated with gastric endoscopic tubulization + lifestyle modification with respect to lifestyle modification / placebo</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in cardiovascular risk profile</measure>
    <time_frame>72 weeks</time_frame>
    <description>To evaluate cardiovascular risk profile in patients treated with gastric endoscopic tubulization + lifestyle modification with respect to lifestyle modification / placebo</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in quality of life (abbreviated health questionnaire SF-36).</measure>
    <time_frame>72 weeks</time_frame>
    <description>To evaluate the following endpoints in patients treated with gastric endoscopic tubulization + lifestyle modification with respect to lifestyle modification / placebo</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Non-Alcoholic Fatty Liver Disease</condition>
  <condition>Obesity</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Diagnostic upper endoscopy plus lifestyle modification.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Endoscopic gastric tubulization with OverStitch® system (Apollo Endosurgery, Austin, TX, USA) plus lifestyle modification.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Endoscopic Gastric Tubulization with OverStitch® system (Apollo Endosurgery, Austin, TX, USA)</intervention_name>
    <description>This endoscopic technique is defined as a gastric restriction by means of sutures of the entire gastric wall, transmurally, in order to simulate a gastric sleeve, in the same way as sleeve gastrectomy surgery. Gastroplasty is performed using an endoscopic suture system (OverStitch, Apollo Endosurgery Inc., Austin, Texas, USA) inserted into a dual-channel endoscope (GIF-2T160, Olympus Medical Systems Corp., Tokyo, Japan).</description>
    <arm_group_label>Treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Lifestyle modification</intervention_name>
    <description>Hypocaloric diet and moderate physical exercise</description>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>Treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Men or women aged between 18 and 75 years (inclusive) at the time of the first
             screening visit.

          2. They must provide signed written informed consent and agree to comply the study
             protocol

          3. Body mass index&gt; 30 kg / m².

          4. Histological confirmation of steatohepatitis in a diagnostic liver biopsy (biopsy
             obtained in the 6 months prior to randomization or during the selection period) with
             at least a score of 1 in each component of the NAS score (steatosis with a score of 0
             to 3, degeneration by ballooning with a score of 0 to 2 and lobular inflammation with
             a score of 0 to 3) and fibrosis of 0 to &lt;4, according to the staging system of CRN
             fibrosis on NASH.

          5. NAS score ≥ 4.

          6. For patients without fibrosis or with stage 1 fibrosis, the NAS score≥5 and one of the
             following conditions (metabolic syndrome (definition NCEP ATP III), DM type II,
             HOMA-IR&gt; 6).

          7. The liver biopsy should have been done with a 16 G trucut needle and the minimum size
             should be 25 mm.

        Exclusion Criteria:

          1. Known heart failure (Grade I to IV of the classification of the New York Heart
             Association).

          2. History of effective bariatric surgery in the 5 years prior to selection.

          3. Patients with a history of clinically significant acute cardiac event in the 6 months
             prior to selection, such as: acute cardiovascular event, cerebrovascular accident,
             transient ischemic attack, or coronary heart disease (angina pectoris, myocardial
             infarction, revascularization procedures).

          4. Weight loss of more than 5% in the 6 months prior to randomization.

          5. Liver cirrhosis.

          6. Non-cirrhotic portal hypertension.

          7. Recent or current background of significant consumption of alcoholic beverages (&lt;5
             years). In the case of men, significant consumption is usually defined as more than 30
             g of pure alcohol per day. In the case of women, it is usually defined as more than 20
             g of pure alcohol per day.

          8. Esophagogastric varices.

          9. Hepatocellular carcinoma

         10. Portal thrombosis.

         11. Pregnancy.

         12. Refusal to give informed consent.

         13. Any medical condition that could reduce life expectancy to less than 2 years,
             including known cancers.

         14. Signs of any other unstable or clinically significant immunological, endocrine,
             hematological, gastrointestinal, neurological, neoplastic or psychiatric disease
             without treatment.

         15. Instability or mental incompetence, so that the validity of the informed consent or
             the ability to comply with the study are uncertain.

             In addition to the above criteria, the patient must not present any of the following
             biological exclusion criteria:

         16. Antibodies positive for the human immunodeficiency virus.

         17. Aspartate aminotransferase (AST) and / or ALT&gt; 10 x upper limit of normal (ULN).

         18. Total bilirubin&gt; 25 μmol / l (1.5 mg / dl).

         19. Standardized international index&gt; 1.4.

         20. Platelet count &lt;100 000 / mm3.

         21. Serum creatinine levels&gt; 135 μmol / l (&gt; 1.53 mg / dl) in men and&gt; 110 μmol / l (&gt;
             1.24 mg / dl) in women.

         22. Significant renal disease, including nephritic syndrome, chronic kidney disease
             (patients with markers of hepatic injury or estimated glomerular filtration rate
             [eGFR] of less than 60 ml / min / 1.73 m2). If an abnormal value is obtained at the
             first screening visit, the eGFR measurement may be repeated before randomization
             within the following time frame: minimum 4 weeks after the initial test and maximum 2
             weeks before the expected randomization. An abnormal repeated eGFR (less than 60 ml /
             min / 1.73 m2) leads to exclusion from the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jose Luis Calleja, Prof</last_name>
    <phone>+34911916000</phone>
    <phone_ext>417175</phone_ext>
    <email>joseluis.calleja@uam.es</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Javier Abad, MD</last_name>
    <phone>+34650814289</phone>
    <email>jabad@salud.madrid.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Jose Luis Calleja</name>
      <address>
        <city>Majadahonda</city>
        <state>Madrid</state>
        <zip>28222</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jose Luis Calleja, Prof</last_name>
      <phone>+34911916000</phone>
      <phone_ext>417175</phone_ext>
      <email>joseluis.calleja@uam.es</email>
    </contact>
    <contact_backup>
      <last_name>Javier Abad, MD</last_name>
      <phone>+34650814289</phone>
      <email>jabad@salud.madrid.org</email>
    </contact_backup>
    <investigator>
      <last_name>Jose Luis Calleja, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Elba Llop, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jose Luis Martinez, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Marta Hernandez, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Javier Abad, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <link>
    <url>http://apolloendo.com/overstitch/</url>
    <description>Apollo website</description>
  </link>
  <reference>
    <citation>Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016 Jul;64(1):73-84. doi: 10.1002/hep.28431. Epub 2016 Feb 22. Review.</citation>
    <PMID>26707365</PMID>
  </reference>
  <reference>
    <citation>Wanless IR, Lentz JS. Fatty liver hepatitis (steatohepatitis) and obesity: an autopsy study with analysis of risk factors. Hepatology. 1990 Nov;12(5):1106-10.</citation>
    <PMID>2227807</PMID>
  </reference>
  <reference>
    <citation>Stepanova M, Rafiq N, Makhlouf H, Agrawal R, Kaur I, Younoszai Z, McCullough A, Goodman Z, Younossi ZM. Predictors of all-cause mortality and liver-related mortality in patients with non-alcoholic fatty liver disease (NAFLD). Dig Dis Sci. 2013 Oct;58(10):3017-23. doi: 10.1007/s10620-013-2743-5. Epub 2013 Jun 18.</citation>
    <PMID>23775317</PMID>
  </reference>
  <reference>
    <citation>Michelotti GA, Machado MV, Diehl AM. NAFLD, NASH and liver cancer. Nat Rev Gastroenterol Hepatol. 2013 Nov;10(11):656-65. doi: 10.1038/nrgastro.2013.183. Epub 2013 Oct 1. Review.</citation>
    <PMID>24080776</PMID>
  </reference>
  <reference>
    <citation>Adams LA, Sanderson S, Lindor KD, Angulo P. The histological course of nonalcoholic fatty liver disease: a longitudinal study of 103 patients with sequential liver biopsies. J Hepatol. 2005 Jan;42(1):132-8.</citation>
    <PMID>15629518</PMID>
  </reference>
  <reference>
    <citation>Angulo P. Diagnosing steatohepatitis and predicting liver-related mortality in patients with NAFLD: two distinct concepts. Hepatology. 2011 Jun;53(6):1792-4. doi: 10.1002/hep.24403.</citation>
    <PMID>21557278</PMID>
  </reference>
  <reference>
    <citation>Neuschwander-Tetri BA. Non-alcoholic fatty liver disease. BMC Med. 2017 Feb 28;15(1):45. doi: 10.1186/s12916-017-0806-8. Review.</citation>
    <PMID>28241825</PMID>
  </reference>
  <reference>
    <citation>Gallego-Durán R, Cerro-Salido P, Gomez-Gonzalez E, Pareja MJ, Ampuero J, Rico MC, Aznar R, Vilar-Gomez E, Bugianesi E, Crespo J, González-Sánchez FJ, Aparcero R, Moreno I, Soto S, Arias-Loste MT, Abad J, Ranchal I, Andrade RJ, Calleja JL, Pastrana M, Iacono OL, Romero-Gómez M. Imaging biomarkers for steatohepatitis and fibrosis detection in non-alcoholic fatty liver disease. Sci Rep. 2016 Aug 12;6:31421. doi: 10.1038/srep31421.</citation>
    <PMID>27514671</PMID>
  </reference>
  <reference>
    <citation>Barr J, Caballería J, Martínez-Arranz I, Domínguez-Díez A, Alonso C, Muntané J, Pérez-Cormenzana M, García-Monzón C, Mayo R, Martín-Duce A, Romero-Gómez M, Lo Iacono O, Tordjman J, Andrade RJ, Pérez-Carreras M, Le Marchand-Brustel Y, Tran A, Fernández-Escalante C, Arévalo E, García-Unzueta M, Clement K, Crespo J, Gual P, Gómez-Fleitas M, Martínez-Chantar ML, Castro A, Lu SC, Vázquez-Chantada M, Mato JM. Obesity-dependent metabolic signatures associated with nonalcoholic fatty liver disease progression. J Proteome Res. 2012 Apr 6;11(4):2521-32. doi: 10.1021/pr201223p. Epub 2012 Mar 15.</citation>
    <PMID>22364559</PMID>
  </reference>
  <reference>
    <citation>Alkhouri N, Feldstein AE. Noninvasive diagnosis of nonalcoholic fatty liver disease: Are we there yet? Metabolism. 2016 Aug;65(8):1087-95. doi: 10.1016/j.metabol.2016.01.013. Epub 2016 Feb 2. Review.</citation>
    <PMID>26972222</PMID>
  </reference>
  <reference>
    <citation>Nobili V, Parkes J, Bottazzo G, Marcellini M, Cross R, Newman D, Vizzutti F, Pinzani M, Rosenberg WM. Performance of ELF serum markers in predicting fibrosis stage in pediatric non-alcoholic fatty liver disease. Gastroenterology. 2009 Jan;136(1):160-7. doi: 10.1053/j.gastro.2008.09.013. Epub 2008 Sep 20.</citation>
    <PMID>18992746</PMID>
  </reference>
  <reference>
    <citation>Ratziu V, Massard J, Charlotte F, Messous D, Imbert-Bismut F, Bonyhay L, Tahiri M, Munteanu M, Thabut D, Cadranel JF, Le Bail B, de Ledinghen V, Poynard T; LIDO Study Group; CYTOL study group. Diagnostic value of biochemical markers (FibroTest-FibroSURE) for the prediction of liver fibrosis in patients with non-alcoholic fatty liver disease. BMC Gastroenterol. 2006 Feb 14;6:6.</citation>
    <PMID>16503961</PMID>
  </reference>
  <reference>
    <citation>Vilar-Gomez E, Martinez-Perez Y, Calzadilla-Bertot L, Torres-Gonzalez A, Gra-Oramas B, Gonzalez-Fabian L, Friedman SL, Diago M, Romero-Gomez M. Weight Loss Through Lifestyle Modification Significantly Reduces Features of Nonalcoholic Steatohepatitis. Gastroenterology. 2015 Aug;149(2):367-78.e5; quiz e14-5. doi: 10.1053/j.gastro.2015.04.005. Epub 2015 Apr 10.</citation>
    <PMID>25865049</PMID>
  </reference>
  <reference>
    <citation>Klebanoff MJ, Corey KE, Chhatwal J, Kaplan LM, Chung RT, Hur C. Bariatric surgery for nonalcoholic steatohepatitis: A clinical and cost-effectiveness analysis. Hepatology. 2017 Apr;65(4):1156-1164. doi: 10.1002/hep.28958. Epub 2017 Feb 21.</citation>
    <PMID>27880977</PMID>
  </reference>
  <reference>
    <citation>Mummadi RR, Kasturi KS, Chennareddygari S, Sood GK. Effect of bariatric surgery on nonalcoholic fatty liver disease: systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2008 Dec;6(12):1396-402. doi: 10.1016/j.cgh.2008.08.012. Epub 2008 Aug 19. Review.</citation>
    <PMID>18986848</PMID>
  </reference>
  <reference>
    <citation>ASGE Bariatric Endoscopy Task Force; ASGE Technology Committee, Abu Dayyeh BK, Edmundowicz SA, Jonnalagadda S, Kumar N, Larsen M, Sullivan S, Thompson CC, Banerjee S. Endoscopic bariatric therapies. Gastrointest Endosc. 2015 May;81(5):1073-86. doi: 10.1016/j.gie.2015.02.023. Epub 2015 Mar 28. Review.</citation>
    <PMID>25828245</PMID>
  </reference>
  <reference>
    <citation>ASGE/ASMBS Task Force on Endoscopic Bariatric Therapy, Ginsberg GG, Chand B, Cote GA, Dallal RM, Edmundowicz SA, Nguyen NT, Pryor A, Thompson CC. A pathway to endoscopic bariatric therapies. Gastrointest Endosc. 2011 Nov;74(5):943-53. doi: 10.1016/j.gie.2011.08.053.</citation>
    <PMID>22032311</PMID>
  </reference>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 9, 2018</study_first_submitted>
  <study_first_submitted_qc>February 1, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">February 8, 2018</study_first_posted>
  <last_update_submitted>February 1, 2018</last_update_submitted>
  <last_update_submitted_qc>February 1, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 8, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Puerta de Hierro University Hospital</investigator_affiliation>
    <investigator_full_name>Jose Luis Calleja</investigator_full_name>
    <investigator_title>Professor and Head of Hepatology Unit of Puerta de Hierro University Hospital</investigator_title>
  </responsible_party>
  <keyword>Non-Alcoholic Fatty Liver Disease</keyword>
  <keyword>NASH</keyword>
  <keyword>Obesity</keyword>
  <keyword>Endoscopic gastric tubulization</keyword>
  <keyword>Non-alcoholic steatohepatitis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Diseases</mesh_term>
    <mesh_term>Fatty Liver</mesh_term>
    <mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

